Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

2445 - Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy

Date

09 Sep 2017

Session

Head and neck cancer, excluding thyroid

Presenters

Victor Lee

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

V.H. Lee1, D.L. Kwong1, T.W. Leung1, C. Choi1, B. O'Sullivan2, K.O. Lam1, V. Lai3, P. Khong3, S. Chan1, C. Ng1, C.C. Tong1, P.Y.P. Ho1, W.L. Chan1, L. Wong1, D.K. Leung1, S. Chan1, A.W. Lee1

Author affiliations

  • 1 Department Of Clinical Oncology, The University of Hong Kong, 000 - Hong Kong/HK
  • 2 Department Of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, M5G2M9 - Toronto/CA
  • 3 Department Of Diagnostic Radiology, The University of Hong Kong, 000 - Hong Kong/HK
More

Resources

Abstract 2445

Background

We incorporated baseline plasma EBV DNA into refinement of stage groups for nasopharyngeal carcinoma (NPC) treated with radical intensity-modulated radiation therapy (IMRT).

Methods

Patients with non-metastatic NPC treated with radical IMRT +/- adjunct chemotherapy based on 7th edition of American Joint Committee on Cancer (AJCC) system were recruited prospectively from 2010 to 2016. All patients had baseline and serial post-IMRT plasma EBV DNA (in copies/ml) measured and were staged with MRI and PET-CT. Recursive partitioning analysis (RPA) with repeated internal validations derived new stage groups with incorporation of baseline plasma EBV DNA. Multivariable analyses were used to calculate adjusted hazard ratios (AHRs) to derive a new set of AHR stages. Comparison of performance of survival prediction among these 3 sets of stage groups was done to find the best-performing stage set.

Results

The cohort included 520 patients treated with IMRT +/- adjunct chemotherapy with a median follow-up of 5.0 years. They were re-staged based on 8th edition of AJCC system. 5-year overall survival (OS) and cancer-specific survival (CSS) were as follows: stage I (OS 89.5%; CSS 100%), II (OS 87.8%; CSS 94.7%), III (OS 85.0%; CSS 90.0%) and IVA (OS 74.4%; CSS 79.9%) (p = 0.058 and p = 0.003 respectively). RPA derived NPC into 3 new stages with corresponding OS and CSS: RPA-I (T1-T4N0-N2 & T1-T2N3 & EBV DNA 2000) (OS 80.5%; CSS 84.1%) and RPA-III (T3-T4N3) (OS 58.2%; CSS 67.1%) (both p 

Conclusions

A novel RPA-based TNM stage groups revealed significantly better survival prediction compared with the 8th edition AJCC and AHR stages.

Clinical trial identification

NCT02476669

Legal entity responsible for the study

Department of Clinical Oncology, The University of Hong Kong and Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital

Funding

SK Yee Medical Foundation

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.